Facts & Figures

Facts

Year of Foundation: 1946

Shareholder structure: owned by 19 shareholders (2010)

Corporate Executive Board:

  • Harald F. Stock, PhD., Chief Executive Officer (CEO) of the Grünenthal corporation
  • Stefan Genten, Chief Financial Officer & Chief Operating Officer
  • Prof. Eric-Paul Pâques, PhD, Global Products

Supervisory Board: 5 members, chairman: Dr. Hasso Kaempfe (2010)

International presence: Companies in 35 countries all over the world; production sites in 6 countries, Headquarters Aachen, Germany

Main business areas: Pain, Gynecology

Top-selling products (Global Brands): Zaldiar®, Tramal®, Transtec®, Norspan®, Versatis®, Belara®, Colistin

 

Figures

Corporate Figures
in Mio €

2009

2008

Revenues

881

864

Revenue Growth vs. PY

2%

2%
Growth Pain Business1 + 5,2% n.a.
   Growth Pain Business Europe2 + 5,3% n.a.
Revenues by region    
   Europe 706  703
   Latin America 143  136
   Rest of world 31 25
Pharma Sales by main products 837 806
   Global Brands Pain 441 427
      Tramal® 143 154
      Zaldiar® / Ixprim® 146 136
      Transtec® / Norspan® 125 120
      Versatis® 28 17
   Other Global Brands 102 95
      Belara® 78 75
      Colistin / Colistin CF 24 20
   Local / Regional Products 294 284
Research & Development Costs 157 162
R&D Costs Ratio 18% 19%
Income before Taxes 116 73
Return on Revenue (IBT / Revenue) 13% 8%
Equity Ratio 58% 52%
Employees Group (annual average) 4.928 4.940

 

Our financial statements are published at www.ebundesanzeiger.de (German)
1 Grunenthal's Pain Business incl. partner franchise in Grunenthal-countries (acc. IMS)
2 Grunenthal's Pain Business Europe incl. partner franchise in Grunenthal-countries (acc. IMS)